PathWhiz

PathWhiz ID	Pathway	Meta Data
PW145921 View Pathway	drug action Canrenoic acid Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:58 Last Updated: October 07, 2023 at 16:58
PW124468 View Pathway	drug action Cannabinoid Signaling Homo sapiens Endogenous cannbinoids the most common being 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide (anandamide, AEA), that acts upon the cannabinoid receptors (CB1), these receptors can also be activated by exogenous cannabinoids such as tetrahydrocannabinol (THC). 2-AG and AEA binds to cannabinoid receptors 1 that goes on to activate g coupled protein Gi and Go, these go on to inhibit adenylate cyclase and calcium voltage gated channels and activates MAP kinases and inward retictifying potassium channels overall eliciting diverse effects. The inhibition of adenylate cyclase leads to reduced ATP production and inhibition of calcium voltage gated channels halts vesicle fusion and release of glutamate and GABA from excitatory and inhibitory pre synaptic terminals respectively. This leads to depolarization induced supression of excitation and inhibition that can cause long term synaptic change that being long term depression (LTD). If endogenous cannabinoids are continously activated and released this leads to continous inactivation causing LTD, with the post synaptic neuron only acting to synthesize and release endogenous cannabinoids to act retrogradely onto the pre synaptic terminals and later taken up again to be degraded. AEA is taken up by the post synaptic neuron to be degraded by fatty acid amino hydrolase (FAAH) and 2-AG is broken down by hydrolytic enzymes and can be converted into prostaglandins which is an inflammatory mediator. Some exogenous cannabinoids such as tetrahydrocannabinol (THC) acts as an agonist to act on the CB1 receptors much like the endogenous cannabinoids to elicit similar effects and cannabidiol (CBD) acts as an antagonist to attenuate the effects of THC. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Selena Created On: January 21, 2021 at 20:16 Last Updated: January 21, 2021 at 20:16
PW122548 View Pathway	metabolic Cannabinoid pathway Cannabis sativa BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Guest: Anonymous Created On: July 27, 2019 at 13:48 Last Updated: July 27, 2019 at 13:48
PW126600 View Pathway	metabolic Cannabinoid Biosynthesis Cannabis sativa Hexanoate is first catalyzed to make hexanoyl-CoA with the enzyme hexanoyl CoA synthase in the cytosol and within the membrane of the cell. Hexanoyl-CoA branches paths to olivetol biosynthesis which creates the byproducts of this pathway. The other pathway is catalyzed by olivetol synthase to make 3,5-dioxodecanoyl-CoA which is catalyzed to make 3,5,7-trioxododecanoyl-CoA. This is similar to the olivetol biosynthesis pathway, however here 3,5,7-trioxododecanoyl-CoA is catalyzed by olivetolic acid cyclase to make olivetolate. This takes place in the cytoplasm. Olivetolate along with geranyl diphosphate is catalyzed by olivetolate geranyltransferase to make cannabigerolate or cannabigerolic acid. This compound branches into three separate pathways each catalyzed by a different enzymes. One pathway is catalyzed by Δ9-tetrahydrocannabinolate synthase along with oxygen to make Δ9-tetrahydrocannabinolate. This compound spontaneously reacts with hydrogen to synthesize the drug Δ9-tetrahydrocannabinol (THC). The second pathway is catalyzed by cannabidiolate synthase and oxygen to make cannabidiolate or cannabidiolic acid. Cannabidiolate spontaneously reacts with hydrogen to synthesize the drug cannabidiol (CBD). The final pathway is catalyzed by cannabichromenate synthase along with an unknown oxidized electron carrier to make cannabichromenate or cannabichromenic acid. This, like the others, spontaneously reacts with hydrogen to synthesize the drug cannabichromene (CBC). BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: January 24, 2022 at 16:30 Last Updated: January 24, 2022 at 16:30
PW145945 View Pathway	drug action Cannabidiol Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 17:02 Last Updated: October 07, 2023 at 17:02
PW124429 View Pathway	metabolic Cannabidiol and delta9-THC Biosynthesis Cannabis sativa BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Eponine Oler Created On: January 11, 2021 at 10:13 Last Updated: January 11, 2021 at 10:13
PW145715 View Pathway	drug action Cangrelor Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:27 Last Updated: October 07, 2023 at 16:27
PW132563 View Pathway	metabolic Cangrelor Drug Metabolism Homo sapiens Cangrelor is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Cangrelor passes through the liver and is then excreted from the body mainly through the kidney. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: September 21, 2023 at 22:25 Last Updated: September 21, 2023 at 22:25
PW122421 View Pathway	drug action Cangrelor Action Pathway Homo sapiens Cangrelor, marketed as Kengreal or Kengrexal, is an antiplatelet drug that targets the P2Y12 receptor of platelets. It was developed as a derivative of ATP that is not enzymatically degraded by the cell. Cangrelor is already active, and is injected intravenously. Here, it binds to the P2Y purinoreceptor 12 on the surface of platelet cells, preventing ADP from binding to and activating it. Cangrelor prevents the activation of the Gi protein associated with the P2Y12 receptor from inactivating adenylate cyclase in the platelet, leading to a buildup of cAMP. This cAMP then activates calcium efflux pumps, preventing calcium buildup in the platelet, which would cause activation, and later, aggregation. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Eponine Oler Created On: March 29, 2019 at 15:49 Last Updated: March 29, 2019 at 15:49
PW127405 View Pathway	drug action Candoxatril Homo sapiens Candoxatril is the prodrug of candoxatrilat that is activated via oral consumption, it is also a neutral endopeptidase inhibitor. It inhibits the metalloprotease enzymes, neutral endopeptidase and angiotensin-converting enzyme; inhibiting these enzymes increases peptides that act to induce vasodilation. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Selena Created On: January 08, 2023 at 11:53 Last Updated: January 08, 2023 at 11:53